At a 52-week low, is this under-the-radar UK stock now an unmissable opportunity to consider?

Stephen Wright outlines a UK stock with explosive growth potential and a commitment to increasing its dividend significantly in the next few years.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Young female business analyst looking at a graph chart while working from home

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It’s unusual to find a UK stock that has outstanding potential for both growth and dividend investors. And it’s almost impossible to find it trading at a bargain price. 

Tristel (LSE:TSTL) however, might be such a stock. It’s at a 52-week low, but the business is growing well and the company just increased its dividend by 8% – with more to come.

What is Tristel?

Tristel’s a stock that investors probably aren’t paying much attention to. But I think they could be missing out if they don’t at least take a closer look.

The company makes disinfectant products for medical equipment. And what sets it apart is its use of chlorine dioxide – rather than chlorine – in its products.

Source: Tristel Investor Presentation February 2025

Chlorine dioxide (CIO2) has a few advantages over chlorine (CI2). Microorganisms can’t build resistance to CIO2, it’s more efficient than CI2, and it doesn’t produce harmful by-products.

In short, Tristel’s products are both effective and require a lot of technical knowledge. And I think this could be a powerful combination going forward.

Outlook

Tristel’s been successful in the UK disinfection market. But the big opportunity is it’s trying to make progress with is the US, which could be huge for a business currently valued at £165m. This however, isn’t straightforward.

The company’s solutions are expensive and convincing hospitals to change from trusted suppliers offering cheaper products might be difficult. Despite this, Tristel’s made progress. Its disinfectant for ultrasound probes has been given regulatory approval and the firm has issued a filing for its ophthalmic devices treatment.

It’s worth noting that, while the US is a huge potential market, it’s not the only growth avenue. The company has also identified Spain, India, and Austria as potential opportunities for 2025.

Dividends

With several international expansion possibilities in progress, it’s natural to think Tristel isn’t likely to be returning cash to shareholders any time soon. But that would be a big mistake. The company currently distributes just under 14p per share in dividends – a yield of 4% at today’s prices. And it’s committed to increasing this by 5% a year going forward. 

Given the uncertainty around its international expansion, that might seem somewhat cavalier. If its plans go as hoped, Tristel will have to invest cash to support its growth. 

The company however, has no debt and the cash on its balance sheet‘s growing. And its latest 8% increase in its interim dividend is in line with the growth from the underlying business.

Risks and rewards

Over the last five years, Tristel’s share price has been all over the place as pandemic-driven demand gave way to unusually high inventory levels. But that volatility should be in the past.

With the stock at a 52-week low, I think investors should consider it. Expansion into the US brings a lot of uncertainty, but the share price offers good value for the risks involved.

If things go well, a £10,000 investment in Tristel today might be generating significant passive income 10 years from now. And the stock could be worth a lot more as well.

Stephen Wright has no position in any of the shares mentioned. The Motley Fool UK has recommended Tristel Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Will the S&P 500 crash in 2026?

The S&P 500 delivered impressive gains in 2025, but valuations are now running high. Are US stocks stretched to breaking…

Read more »

Teenage boy is walking back from the shop with his grandparent. He is carrying the shopping bag and they are linking arms.
Investing Articles

How much do you need in a SIPP to generate a brilliant second income of £2,000 a month?

Harvey Jones crunches the numbers to show how investors can generate a high and rising passive income from a portfolio…

Read more »

Investing Articles

Will Lloyds shares rise 76% again in 2026?

What needs to go right for Lloyds shares to post another 76% rise? Our Foolish author dives into what might…

Read more »

Investing Articles

How much passive income will I get from investing £10,000 in an ISA for 10 years?

Harvey Jones shows how he plans to boost the amount of passive income he gets when he retires, from FTSE…

Read more »

Investing Articles

Down 34% in 2025 — but could this be one of the UK’s top growth stocks for 2026?

With clarity over research funding on the horizon, could Judges Scientific be one of the UK’s best growth stocks to…

Read more »

piggy bank, searching with binoculars
Investing Articles

Can the rampant Barclays share price beat Lloyds in 2026?

Harvey Jones says the Barclays share price was neck and neck with Lloyds over the last year, and checks out…

Read more »

Investing Articles

Here’s how Rolls-Royce shares could hit £25 in 2026

If Rolls-Royce shares continue their recent performance, then £25 might be on the cards for 2026. Let's take a look…

Read more »

Departure & Arrival sign, representing selling and buying in a portfolio
Investing Articles

Prediction: in 2026 the red-hot Rolls-Royce share price could turn £10,000 into…

Harvey Jones can't believe how rapidlly the Rolls-Royce share price has climbed. Now he looks at the FTSE 100 growth…

Read more »